Abcam, ab131168, Anti-AKT2 antibody [EP1676]

Size: 20µL / 100µL / 1mL
Rabbit Recombinant Monoclonal AKT2 antibody. Suitable for WB and reacts with Human, Mouse, Rat samples. Cited in 14 publications.
Key facts
Host species:Rabbit,
Clonality:Monoclonal,
Clone number:EP1676,
Isotype:IgG,
Carrier free:No,
Reacts with:Mouse, Rat, Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:The exact immunogen used to generate this antibody is proprietary information.

Product details:
This product has switched from a hybridoma to recombinant production method on 9th February 2024.
Patented technology
Our RabMAb
technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to
RabMAb® patents
What are the advantages of a recombinant monoclonal antibody?
This product is a recombinant monoclonal antibody, which offers several advantages including:
- High batch-to-batch consistency and reproducibility
- Improved sensitivity and specificity
- Long-term security of supply
- Animal-free batch production
For more information, read more on
recombinant antibodies

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.2 - 7.4Preservative: 0.01% Sodium azideConstituents: PBS, 40% Glycerol (glycerin, glycerine), 0.05% BSA, Shipped at conditions-Blue Ice, Appropriate short-term storage duration-1-2 weeks, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Stable for 12 months at -20°C

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
The AKT2 protein also known as protein kinase B beta is a serine/threonine kinase with a mass of approximately 56 kDa. It plays a critical mechanical role in cell survival and cell growth. AKT2 is an isoform of the AKT family and shares structural similarity with other AKT proteins. It is widely expressed in various tissues with high levels in insulin-responsive tissues such as skeletal muscle adipose tissue and liver. The AKT2 protein is an essential component in transmitting cellular signals related to growth and metabolism.
Biological function summary
The protein engages in controlling glucose transport and metabolism. As part of its biological functions AKT2 becomes phosphorylated and activated in response to insulin signaling and does not work as a part of a larger complex but interacts with other proteins. It plays a significant role in maintaining normal insulin sensitivity in tissues by facilitating the uptake and storage of glucose. Additionally the protein influences cell cycle progression and can affect apoptotic responses contributing to processes like protein synthesis and cell proliferation.
Pathways
AKT2 involves signaling mechanisms that include the PI3K/AKT/mTOR pathway and the insulin signaling pathway. These pathways are deeply connected to cellular growth and metabolic regulation. AKT2 works closely with proteins such as PI3K which phosphorylates phosphoinositides and mTOR that control protein synthesis by activating downstream targets. These interactions highlight the integration of AKT2 in nutrient-sensing pathways and how it aids the regulation of energy status in response to external stimuli.
AKT2 is notably linked to conditions such as type 2 diabetes and cancer. These diseases often involve dysregulated signaling pathways where AKT2 plays a significant role. In type 2 diabetes AKT2's link to insulin signaling becomes critical and its aberrant activity can lead to insulin resistance. In cancer the AKT2 protein interacts with PTEN a tumor suppressor that negatively regulates the PI3K/AKT pathway often leading to unregulated cell growth when mutated or inhibited. The understanding of AKT2's involvement in these diseases assists in developing potential therapeutic strategies targeting its dysregulation.